Clinical Trials Logo

Clinical Trial Summary

Intensive care unit patients have multiple risk factors for venous thromboembolism. Venous thromboembolism leads to significant morbidity and can be fatal. Unfractionated heparin and low molecular weight heparin are commonly used to prevent venous thromboembolism. Heparin induced thrombocytopenia, an untoward consequence of exposure to heparin, is an immune disorder that may develop in patients treated with heparin products. Determining the prevalence of heparin induced thrombocytopenia and its relationship to preventive and therapeutic heparin and low molecular weight heparin will help clinicians more appropriately choose methods of venous thromboembolism prophylaxis and treatment in the critically ill, ICU population.

The objective of this study is to determine the prevalence of heparin-induced antibodies on admission to the ICU and the development of new heparin-antibodies during the first week of hospitalization.


Clinical Trial Description

Venous Thromboembolism (VTE) is common in the intensive care unit (ICU); VTE leads to significant morbidity and is fatal in 30% of undiagnosed pulmonary emboli and 8% when PE is appropriately treated. Intensive care unit (ICU) patients have multiple risk factors for VTE and tend to be at higher risk than non-ICU patients. Risk factors specific to ICU patients include immobility, central venous catheters, sepsis or infection, need for vasopressors, mechanical ventilation, surgery, trauma, and increasing age. Guidelines exist for the prevention of VTE, and VTE prophylaxis is strongly recommended. Given the high rate of VTE and the attendant morbidity and mortality, most ICU's routinely provide VTE prophylaxis which is individualized according to risk-benefit analysis with respect to thrombosis and bleeding risk. Prophylaxis for patients at risk of bleeding is accomplished by using mechanical compression devices while those without bleeding risk are administered medical prophylaxis which is felt to be more effective.

Recently, it has become apparent that medical prophylaxis is not without risk and that the risk-benefit analysis should also include the risk of developing heparin induced thrombocytopenia (HIT) or heparin induced thrombocytopenia with thrombosis (HITT).

Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) are commonly used to prevent VTE in ICU and non-ICU patients. HIT, an untoward consequence of exposure to heparin is an immune disorder that may develop in patients treated with heparin products. HIT is antibody mediated, usually due to IgG antibodies directed against epitopes on the platelet surface comprised of the heparin-platelet factor 4 complex. HIT is generally characterized by a decrease in platelet count to less than 100 X 109/L, or a 50% decrease from baseline, after exposure to heparin. HIT is typically observed after 5 to 10 days of treatment. Alternatively, patients with previous exposure to heparin can develop HIT in two days while heparin naive patients may develop HIT in about 10 days. The platelet count usually returns to normal several days after discontinuing heparin with or without therapy, though the risk for thrombosis persists for up to 3 months due to the persistence of antibodies.

Using an ELISA assay heparin-induced antibody formation is found in up to 50% of patients exposed to UFH. However, the serotonin release assay (SRA) which is believed to be more specific for HIT detects antibody formation in about 20% of patients. Five percent of patients receiving UFH develop thrombocytopenia (HIT) and half of these patients go on to develop heparin induced thrombocytopenia with thrombosis (HITT) which results in venous and arterial complications which can be life threatening, or result in loss of extremities.

The occurrence of HIT varies widely between clinical populations and is dependent on the type of heparin used, i.e. UFH vs. LMWH. The highest incidence reported to date has been in the cardiac and orthopedic populations and is unknown in the ICU population. Warkentin, et al found in a study of 655 hip surgery patients that 2.7% randomized to UFH developed HIT while none receiving enoxaparin (LMWH) developed HIT. This variability in development of antibodies and the HIT syndrome makes it critically important to understand heparin induced antibody formation as a precursor to HIT and HITT.

Determining the prevalence of HIT and its relationship to preventive and therapeutic UFH and LMWH will help clinicians more appropriately choose methods of VTE prophylaxis and treatment in the critically ill, ICU population.

Objectives To determine the prevalence of heparin-induced antibodies on admission to the ICU and the development of new heparin-antibodies during the first 7 +/- 2 days of hospitalization. Secondary objectives include: determining the incidence of heparin antibody formation in patients treated with UFH, LMWH and mechanical prophylaxis (MPX); and to compare the incidence of heparin antibodies between different ICU populations. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT00283322
Study type Observational
Source The University of Texas Health Science Center, Houston
Contact
Status Completed
Phase N/A
Start date November 2004
Completion date May 2006

See also
  Status Clinical Trial Phase
Withdrawn NCT00759083 - Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients Phase 4
Completed NCT00412464 - Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis Phase 1
Completed NCT00456326 - Heparin-Induced Thrombocytopenia Registry N/A
Terminated NCT00673439 - Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT) Phase 2
Active, not recruiting NCT00198575 - A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients N/A
Not yet recruiting NCT05586854 - Multicenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia N/A
Not yet recruiting NCT03269019 - Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia N/A
Not yet recruiting NCT06066762 - Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.
Terminated NCT03809481 - Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban Phase 3
Completed NCT05325346 - A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects Phase 1
Recruiting NCT02717039 - Pharmacogenomics of Heparin-Induced Thrombocytopenia
Completed NCT02526485 - Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2
Completed NCT00748839 - Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical N/A
Recruiting NCT05783895 - Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery
Not yet recruiting NCT04782843 - Evaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care.
Completed NCT00198588 - Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia Phase 3
Recruiting NCT04842760 - PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer
Terminated NCT01598168 - Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia Phase 3
Completed NCT01654848 - Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients N/A
Withdrawn NCT00603824 - Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT) Phase 4